Intech Investment Management LLC Invests $74,000 in Nkarta, Inc. (NASDAQ:NKTX)

Intech Investment Management LLC purchased a new stake in Nkarta, Inc. (NASDAQ:NKTX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 16,274 shares of the company’s stock, valued at approximately $74,000.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Nkarta by 26.0% during the first quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock valued at $21,255,000 after acquiring an additional 405,753 shares during the last quarter. GAMMA Investing LLC lifted its stake in Nkarta by 1,887.0% during the second quarter. GAMMA Investing LLC now owns 4,729 shares of the company’s stock worth $28,000 after purchasing an additional 4,491 shares in the last quarter. Simplicity Wealth LLC boosted its position in shares of Nkarta by 136.8% during the second quarter. Simplicity Wealth LLC now owns 37,486 shares of the company’s stock worth $222,000 after buying an additional 21,659 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Nkarta by 80.2% in the second quarter. Bank of New York Mellon Corp now owns 172,162 shares of the company’s stock valued at $1,017,000 after buying an additional 76,612 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Nkarta by 65.1% during the 2nd quarter. Rhumbline Advisers now owns 84,011 shares of the company’s stock worth $496,000 after acquiring an additional 33,117 shares in the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NKTX has been the topic of a number of research reports. Raymond James upgraded shares of Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price on the stock in a report on Wednesday, August 14th. Rodman & Renshaw started coverage on shares of Nkarta in a report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 price objective on the stock. RODMAN&RENSHAW upgraded Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Mizuho lowered their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a report on Thursday, November 21st. Finally, HC Wainwright reduced their price target on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $15.00.

Nkarta Price Performance

NKTX stock opened at $2.58 on Monday. Nkarta, Inc. has a 12 month low of $2.38 and a 12 month high of $16.24. The company has a market cap of $182.07 million, a price-to-earnings ratio of -1.37 and a beta of 0.82. The company has a fifty day moving average price of $3.34 and a 200 day moving average price of $4.96.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.